Gastric Cancer Stage IV

LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study

Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis

Conversion Surgery for Gastric Cancer With Peritoneal Metastases (CONVERGENCE)

Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer

Conversion Surgery After Target Therapy or Immunotherapy in Stage IV Gastric Cancer

Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab

Real-world Data of Paclitaxel and Ramucirumab Compared to Other Treatment Regimens in Advanced Gastric Cancer

Stomach Cancer Exosome-based Detection

Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6

Tislelizumab Combined With Chemotherapy in First-line Treatment of AGC

Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer

Trastuzumab to Patients With Advanced Gastric Cancer With HER2 Positive Expression in CTC

PD-1 Antibody in EBV Positive Metastatic Gastric Cancer Patients.

Predictive Role of Circulating Angiogenic Factors for Second-line Paclitaxel and Ramucirumab.

Efficacy and Safety of Sintilimab Combined Intraperitoneal and Intravenous Paclitaxel Plus Oral S-1 in Gastric Cancer Patients With Peritoneal Metastasis

Efficacy and Safety of Toripalimab Combined With Docetaxel or Nab-paclitaxel in Patients With Advanced Gastric Cancer

To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors

Maintenance Treatment With S-1 in Gastric Cancer Patients